CD274 and neoplasm: An example is a case report on a patient resistant to multiple therapies, including R-CHOP plus enzastaurin and gentamicin + oxaliplatin (GemOx) with lenalidomide and selinexor, who harbored a CD274 amplification and exhibited a high PD-L1 tumor proportion score.